Korsana reports Q3 2026 results, advances KRSA-028 toward the clinic

Korsana Biosciences, Inc. reported financial results for the third quarter ended September 30, 2026, on November 5, 2026, alongside a corporate update on its lead Alzheimer's disease program.

The company said it advanced KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data in patients with Alzheimer's disease anticipated by year-end 2027 or the first quarter of 2028.¹ KRSA-028 is described as a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease that uses Therapeutic Targeting (THETA), a CNS shuttle technology the company says was developed with Paragon Therapeutics and is intended to raise drug concentrations in the brain compared to earlier shuttle technologies.¹

Korsana also disclosed that preclinical data on KRSA-028 were accepted for presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, covering pharmacokinetic and hematologic parameters, binding affinity, and phagocytic activity, with the poster (Poster Number P338, titled "Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation") scheduled for Wednesday, November 18, 2026.¹

On the corporate side, the company completed its merger with Cyclerion Therapeutics along with a concurrent $380 million private placement in September 2026.¹ It also added to its leadership, naming Matthew Leoni, M.D. as Chief Medical Officer, Gan Wei, Ph.D. as Chief Technical Officer, and Heidi Henson to its board as Chair of the Audit Committee.¹

On finances, Korsana reported cash and cash equivalents of approximately $456.2 million as of September 30, 2026, which it said is expected to fund operations into 2029.¹